HER2 Assessment by Bright‐field Dual in Situ Hybridization in Cell Blocks of Recurrent and Metastatic Breast Carcinoma

Cancer cytopathology - United States
doi 10.1002/cncy.22184
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Assessment of Risk Factors in Metastatic / Recurrent Tall Cell Variant of Papillary Thyroid Carcinoma

Endokrynologia Polska
EndocrinologyMetabolismDiabetes
2015English

Comparison of Fluorescence In-Situ Hybridisation With Dual-Colour In-Situ Hybridisation for Assessment of HER2 Gene Amplification of Breast Cancer in Hong Kong

Hong Kong Medical Journal
Medicine
2016English

Advanced Metastatic Breast Carcinoma in Sickle Cell Disease

Universa Medicina
2019English

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2016English

Assessment of HER2 Status in Breast Cancer: Overall Positivity Rate and Accuracy by Fluorescence in Situ Hybridization and Immunohistochemistry in a Single Institution Over 12 Years: A Quality Control Study

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Metastatic Squamous Cell Carcinoma in Situ in Vulva Associated With Pigmentation.

The Journal of the Japanese Society of Clinical Cytology
1984English

Necessity of in Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients With Equivocal HER2 Immunohistochemistry Results

Journal of Breast Disease
2018English

Single-Cell in Situ RNA Profiling by Sequential Hybridization

Nature Methods
BiochemistryBiotechnologyCell BiologyMolecular Biology
2014English

Breast Ductal Carcinoma in Situ

International Journal of Surgical Oncology
SurgeryOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy